CAR T Therapy and the Future of Cellular Treatments, ft. Dr. Fred Locke

Dr. Patrick Hwu welcomes Dr. Fred Locke, chair of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. Dr. Locke shares his personal and professional journey into CAR T-cell therapy, shaped in part by his own father’s cancer battle. A leader in pivotal clinical trials, Dr. Locke explains how engineered T cells are transforming lymphoma treatment — offering durable, sometimes curative responses. He discusses the science behind CAR T-cell manufacturing, trial design and its growing applicatio to diseases like multiple myeloma, along with future innovations in cellular immunotherapy. What You’ll Learn from Dr. Locke How a personal family experience inspired Dr. Locke’s passion for immunotherapy The story behind pivotal CAR T clinical trials (ZUMA-1 and ZUMA-7) and their FDA approvals What makes CAR T therapy so effective in blood cancers — and the challenges with solid tumors Innovative approaches on the horizon: donor-derived CAR Ts, TIL therapy, and engineered TCR therapies Why diet, exercise, and prehabilitation may improve immune cell therapy outcomes How Moffitt is scaling CAR T for outpatient treatment and community hospital access Access more show notes, links and transcript here: https://www.moffitt.org/about-moffitt/podcasts/immunoverse/future-of-cellular-treatments/